The BCL6 gene is often structurally altered and probably 'misregulated' in two different types of human B-cell nonHodgkin lymphomas (BNHL) thought to arise from germinal centre B cells. BCL6 encodes a BTB/POZ and zinc finger protein whose biochemical properties support a role as a DNA-binding transcriptional repressor and disclose, in part, the underlying mechanisms. In contrast, the study of the 'oncogenic' structural alterations of BCL6 in BNHL and of its cellular functions gives rise to much more heterogeneous data with no obvious unifying picture so that how and even whether BCL6 contributes to lymphomagenesis remains unclear. This review will summarize the current knowledge about the 'oncogenic' alterations and cellular functions of BCL6 and, based on some results, will propose the following hypotheses: (1) In various systems, including in memory T cells and also in germinal centre B cells and possibly in certain postmitotic cells, BCL6 may act by stabilizing a particular stage of differentiation. (2) Both its ambivalent effects on cell survival and the heterogeneous consequences of its alterations in BNHL suggest that BCL6 can be oncogenic not only upon overexpression or persistent expression, as often proposed, but also, similar to some of its relatives, upon 'accidental' downregulation.
Introduction
The BCL6 gene, also known as BCL5 and LAZ3, was initially cloned by virtue of its disruption in certain types of human B-non an Hodgkin lymphomas (BNHL). It encodes one of the most studied so-called 'POK' proteins, harbouring N-terminal POZ (or BTB) domain that mediates protein/protein interactions including selfinteractions, and a varying number (six in the case of BCL6) of C-terminal Kru¨ppel-like C2H2-type zinc fingers. Like many other POK proteins, BCL6 is able to bind DNA through its C-terminal zinc fingers (thereafter referred to as BCL6DBD, DNA-bindingdomain) with a strong affinity for a particular sequence in vitro, and represses transcription when bound to this sequence in vivo (Figure 1 ) (for a recent review on transcriptional repression by BCL6, see Dent et al., 2002) . It does so in part by recruiting, directly and indirectly, class I and II histone deacetylases (HDACs) Lemercier et al., 2002) . Despite these important findings, its cellular function, including how, and even whether, it contributes to lymphomagenesis remains unclear. Indeed, the many biological activities reported for BCL6 appear highly diverse and even sometimes contradictory at first glance. In this review, the results regarding the cellular functions of BCL6 will be summarized and an attempt will be made to reconcile these functions beyond their diversity, and to understand the possible reasons of their apparent discrepancies. Moreover, bearing in mind the structural alterations of BCL6 in BNHL, this overview will highlight what these results bring to the understanding of the possible relationship between BCL6 and human oncogenesis.
Alterations of the BCL6 5 0 noncoding region in normal and transformed B cells
The BCL6 gene is originally linked to human oncogenesis. It has been cloned because it maps to a major translocation breakpoint cluster affecting the 3q27 chromosomal region in two types of BNHL: follicular lymphomas (FL) and diffuse large B-cell lymphomas (DLCL), which both presumably derive from germinal centre (GC) B cells (Kerckaert et al., 1993; Lo Coco et al., 1994; Ye et al., 1993 Ye et al., , 1997 Miki et al., 1994; Ohno and Fukuhara, 1997; Alizadeh et al., 2000; Lossos and Levy, 2000) . As a result of numerous 3q27 translocations, BCL6 fuses to one of at least 20 'partner' loci, including three Ig gene loci, which generally gives rise to a chimeric X-BCL6 transcript (Chen et al., 1998b; Galiegue-Zouitina et al., 1999; Yoshida et al., 1999a; Ueda et al., 2002a) . Importantly, the breakpoints spare the BCL6 coding region, which presumably remains unchanged, as they often are clustered in a conserved 4 kb region -called MTC or MBR (major translocation cluster/major breakpoint region) -spanning the BCL6 promoter, its first noncoding exon and the intronic region immediately downstream (Kerckaert et al., 1993; Ye et al., 1993; Otsuki et al., 1995) . In addition, in some cases of BNHL but independent of the translocations, the MTC/MBR region undergoes 'large' deletions, which overlap in a short region of the 5 0 side of the first intron, while the other copy of BCL6 may also be altered or lost (Nakamura et al., 1996; Bernardin et al., 1997) . Overall, a lesion of BCL6 revealed by a rearrangement in MTC/MBR occurs in 5-15% of FL and 25-35% of DLCL, and is therefore one of the most frequent genetic abnormalities in BNHL (Ohno and Fukuhara, 1997) . However, a 3q27 translocation does not necessarily mean a BCL6 structural alteration: other breakpoints exist, such as in ABR (alternative breakpoint region) located 200-270 kb telomeric to MTC/ MBR, and therefore outside the defined BCL6 locus (Ohno and Fukuhara, 1997; Chen et al., 1998a) . In addition, human BCL6 is also frequently subject to multiple somatic point mutations and, more rarely, microdeletions (up to 8 bp) in its first exon and in a 700 bp region -termed MMC for major mutations cluster -again in the 5 0 side of its first intron (Migliazza et al., 1995) . Although located in a subdomain of MTC/ MBR, these 'microalterations', which often affect both BCL6 alleles, are independent of lymphomagenesis, as they also occur in vivo in normal GC B cells and are induced upon appropriate stimuli in a model of GC Bcell differentiation in vitro (Pasqualucci et al., 1998; Shen et al., 1998; Zan et al., 2000) . In fact, they share typical features of those affecting the IgV sequences in GC B cells, which strongly suggests that BCL6 and IgV are concomitantly targeted by the same (or closely related) somatic hypermutation machinery (Zan et al., 2000 (Zan et al., , 2001 . So far, although multiple genes were shown to be aberrantly targeted by the hypermutation machinery in some malignant derivatives of GC B cells, only two genes, -in addition to IgV -BCL6 and CD95/Fas, undergo such physiological 'microalterations' during the transit of normal human B cells through GC (Pasqualucci et al., 2001) . Thus, the high proportion of BNHL cases with 'microalterations' in BCL6 reflects the frequent GC or post-GC origin of these tumours and not their malignant nature. However, it remains possible that a subset of these 'microalterations' alters BCL6 regulation and hence may somehow bias the fate of GC B cells, possibly toward lymphomagenesis (Zan et al., 2000) . Accordingly, it was reported that FL transformation into aggressive DLCL is sometimes associated with the accumulation of new point mutations in the 5 0 noncoding region of BCL6 (Lossos et al., 2001) (Figure 2 ).
BCL6 'misregulation' and lymphomagenesis
The incidence and nature of BCL6 alterations suggest a causal implication of its 'misregulation' in BNHL. BCL6 undergoes two changes upon translocations: its 5 0 untranslated region is altered (which is also caused by deletions and 'microalterations'), and it is placed under the control of a heterologous promoter Ohno and Fukuhara, 1997) . The initial analysis of BCL6 expression in both rearranged and nonrearranged BNHL showed similar levels of BCL6 transcript (Otsuki et al., 1995; Ohno and Fukuhara, 1997) . However, the fact that two differently altered BCL6 alleles are differentially expressed in some DLCL-derived cells indicates that at least some alterations indeed affect the regulation of BCL6 expression Chen et al., 1998a; Dalla-Favera et al., 1999) . But what does 'misregulation' precisely mean given the diversity of the alterations? Numerous partner-genes (hereafter referred to as the 'X' genes) providing the 'host' promoter to Figure 1 The BCL6 protein and its functional domains. Several functional domains of BCL6 mediate protein/protein interactions, transcriptional repression, post-translational regulation and specific binding to DNA. * The binding to SMRT, NcoR and BcoR involves mostly a conserved charged pocket spanning aa 25-54. **The isolated BTB/POZ domain of BCL6 is not sufficient to bind PLZF or LRF but may, however, contribute to their interaction in cooperation with other domain(s), including the DBD region. *** Evi9 has been shown to bind in vitro to a BCL6 fragment spanning amino acids 1-180, which is slightly longer than the BTB/POZ domain. ****Binding to mSIN3A has been demonstrated using yeast two-hybrid assays and requires the N-terminus of this region (aa 191-264) . Another subdomain (aa 370-386) completely conserved in the highly related BAZF protein also appears essential for the repressive activity of this region, and this activity is counteracted by the HDAC inhibitor, trichostatin A. Note that the IRF4 transcription factor, which is able to interact with -and is inhibited by -BCL6, is not mentioned here, as the interacting domains are not mapped on BCL6 (Gupta et al., 2001) . BTB/POZ: Bric a`brac, Tramtrack, Broad complex/Pox virus and Zinc finger. DBD region: DNA-binding region. HDACs: histone deacetylases. (References: Dhordain et al., 1995 Dhordain et al., , 1997 Dhordain et al., , 1998 Dhordain et al., , 2000 Chang et al., 1996; Niu et al., 1998; Okabe et al., 1998; Davies et al., 1999; Huynh et al., 2000; Nakamura et al., 2000; Zhang et al., 2001; Dent et al., 2002; Lemercier et al., 2002; Melnick et al., 2002; Vasanwala et al., 2002) Ambivalent role of BCL6 O Albagli-Curiel translocated BCL6 have been cloned (reviewed recently in Chen et al., 2001; Ueda et al., 2002a) . Beyond their diversity, the 'X' genes often display throughout the Bcell lineage an expression broader than that of the unaltered BCL6 (Chen et al., 1998b (Chen et al., , 2001 , suggesting that 'misregulation' means an abnormally persistent expression of the translocated BCL6 at the late stages of B cell differentiation (see below). This was directly supported by several data. First, BCL6 translocations abrogate its normal transcriptional shut-off upon stimulation of CD40 receptor, a regulator of GC differentiation, in several DLCL-derived cell lines (Allman et al., 1996; Cattoretti et al., 1997; Gupta et al., 1999) . Similarly, other BCL6 alterations associated with BNHL, including some 'microalterations', are suspected to relieve BCL6 from negative (possibly auto-) regulations, although studies based on transiently transfected artificial reporters do not necessarily recapitulate the transcriptional control of endogenous BCL6 (Kikuchi et al., 2000; Pasqualucci et al., 2000; Ueda et al., 2002a) . Finally, a study of several DLCL cases reveals that point mutations in a short intronic mutational 'hotspot' are associated with a higher BCL6 expression (Artiga et al., 2002) . However, it appears increasingly clear that BCL6 alterations in BNHL are not equivalent with respect to their consequences on BCL6 expression. Indeed, mutations in another more proximal intronic hotspot have no effect on BCL6 expression (Artiga et al., 2002) . Moreover, it was recently reported that BCL6 translocations in Ig and non-Ig loci lead to high and low BCL6 expression, respectively, which may correspond to two kinds of DLCL with distinct phenotypic and clinical features (Alizadeh et al., 2000; Ueda et al., 2002b) . This important result reveals that the 'X' partner gene does not necessarily impart its transcriptional control to BCL6 -probably because the translocation mingles heterologous regulatory elements -and suggests that abnormally low BCL6 expression can also contribute to B lymphomagenesis (Ueda et al., 2002a) . Finally, the occasional occurrence of the reciprocal BCL6-X transcripts indicates that, upon BCL6 translocation, the 'X' genes can be placed under the control of the BCL6 promoter and might thereby also be 'misregulated' (Galiegue-Zouitina et al., 1999; Preudhomme et al., 2000) . This could contribute to differential phenotypic or clinical features among BNHL cases, or even, as suggested when the 'X' gene encodes the GTP-binding RhoH/TTF protein, to the tumorigenic process itself (Preudhomme et al., 2000) . In fact, as transgenic mice expressing lymphoma-associated BCL6 alleles in B cells are still missing and given that no lymphomas have been reported in the short-lived BCL6À/À mice nor in mice overexpressing BCL6 in T cells (see below), it remains unclear as to whether BCL6 misregulation, and if so which misregulation, causes BNHL. The cases of 3q27 breakpoints far from the defined BCL6 locus raise further questions and suggest the involvement of other unknown genes that may be subject to rearrangement (Chen et al., 1998a) .
Other POK proteins and human cancers
Given such uncertainties, it is noteworthy that three other genes encoding POK proteins are also altered in malignancies. The PLZF gene is fused to the retinoic acid receptor alpha in some cases of acute promyelocytic leukaemia (Chen et al., 1993) . The APM1 gene is altered upon human papillomavirus integration in one case of cervical cell line (Reuter et al., 1998) . Finally, the HIC1 gene may be involved in many human solid and haematopoietic tumours, in addition to its proposed role in a developmental disorder known as MillerDieker syndrome (Carter et al., 2000) . An important common feature for these three genes is that they appear, based on both expression and functional data, somehow inactivated, and not hyperactive, in malignancies (as well as in Miller-Dieker syndrome for HIC1). The RARa/PLZF chimera, which cooperates with the reciprocal PLZF/RARa chimera to induce leukaemia in transgenic models, binds DNA onto PLZF-binding sites. RARa/PLZF probably acts by competitively inhibiting PLZF, since deletion of PLZF phenocopies its effect on leukaemogenesis (Licht et al., 1996; He et al., 2000) . APM1 is expressed in normal In BNHL, BCL6 expression may be deregulated through translocation and promoter substitution, as well as deletions and particular 'microalterations' (point mutations and more rarely short deletions) affecting its first noncoding exon and an intronic region immediately downstream. Although independent, these three kinds of alterations can be combined and result in biallelic multiple alterations. Note that the 5 0 noncoding region of BCL6 is also subject to 'microalterations' in normal GC B cells (see text). Sometimes, these events may lead to persistent BCL6 expression at late stages of B-cell differentiation, where it is normally shut off, thereby possibly preventing terminal differentiation and increasing cell survival. This may in turn make the B cells more prone to undergo 'successfully' other genetic alterations, and to progress toward a transformed phenotype. These secondary alterations can include 'microalterations' within BCL6 that would give a further selective advantage to the cells. Indeed, it has been reported that the transformation from 'indolent' FL to 'aggressive' DLCL is sometimes associated with the accumulation of new point mutations in the 5 0 noncoding region of BCL6. Note that some oncogenic events may precede the alterations of BCL6. Moreover, other genetic alterations may lead to BCL6 downregulation, which could also contribute to the genesis of another subset of BNHL cases (see text)
Ambivalent role of BCL6 O Albagli-Curiel cervical keratinocytes but not in the majority of cervical carcinoma cell lines and inhibits cell growth of Hela and Caski cells when overexpressed (Reuter et al., 1998) . Finally HIC1, which also induces growth arrest upon overexpression, is hypermethylated and underexpressed in many cancers (hence its name, Hypermethylated in Cancer) but is upregulated by the tumour suppressor p53 (Wales et al., 1995; Carter et al., 2000; Guerardel et al., 2001) . Overall, these data suggest that POK transcription factors appear as 'antioncoproteins' whose loss or inactivation contributes to various forms of cancers.
BCL6 as a pro cell survival gene
BCL6 can inhibit apoptosis
Many overexpressed proto-oncogenes involved in haematopoietic malignancies act by preventing apoptosis (Adams and Cory, 1998; Nason-Burchenal et al., 1998) . That such a mechanism may occur when BCL6 loses negative regulations in BNHL has received experimental support. Indeed, C2C12 mouse myocytes were more prone to undergo apoptosis upon serum starvation, which is a culture condition favouring terminal differentiation, when BCL6 expression was lowered by the mean of antisense RNA (Kumagai et al., 1999) . This phenotype, which appears to be dependent on caspase 3 activation, is clearly caused by the BCL6 'depletion', as it is rescued by concomitant overexpression of BCL6 (Kumagai et al., 1999) . Moreover, knockout experiments demonstrate that heterozygous and, to a greater extent, homozygous loss of BCL6 abnormally prolongs the wave of apoptosis normally affecting the differentiating male germ cells at the spermatocyte stage in young adult animals (Kojima et al., 2001) . This increased apoptosis is accompanied by the induction of the BAX protein and mimics that induced by a hyperthermic shock on the testes of normal mice. This might be an intrinsic defect, since spermatocytes express BCL6 (Yoshida et al., 1996; Kojima et al., 2001) . Consistent with these findings, PCDC2 (which is highly homologous to RP8), a rat gene rapidly induced following proapoptotic stimuli in thymocytes, has been proposed to be a BCL6 target gene in B cells, although it has been shown to be responsive to a BCL6DBD-VP16 chimera (Baron et al., 2002) but not, so far, to BCL6 itself. Altogether, these data were interpreted as the indication that BCL6 shields the cells against various proapoptotic 'stresses', including trophic and thermic stresses, an activity that may be relevant to explain its proposed role in BNHL persistently expressing BCL6 (Kojima et al., 2001) (Figure 3 ).
Other protective roles of BCL6
Confirming the notion that BCL6 is a protective protein, the heart muscle has been reported to degenerate in BCL6À/À mice after 4 weeks of age (Yoshida et Figure 3 Multiple roles of BCL6 in cell survival and differentiation. BCL6 has been shown to exert contrasting influences on cell survival. Indeed, in many cell lines, enforced expression of BCL6 leads to apoptosis. Moreover, in one case of primary cells, namely macrophages cultured in vitro, endogenous BCL6 decreases cell survival. On the contrary, in some other primary cells, enforced expression of BCL6 improves cell survival and endogenous BCL6 protects established skeletal muscle cells against apoptosis upon serum deprivation in vitro, as well as spermatocytes against apoptosis in vivo. Moreover, endogenous BCL6 has also been proposed to shield cardiac myocytes against degeneration in vivo, and appears to be essential for GC B cells, although the reasons for the lack of GC in BCL6À/À mice are not fully understood. The protective role of BCL6 may partly correspond to a stabilization of a particular differentiation state. Such a 'maintenance' activity of BCL6 has been evidenced in memory T cells but can be envisioned in various other cell types, including GC B cells
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O Albagli-Curiel 1999b). Importantly, although myocarditis and heart destruction in these animals were initially supposed to be an indirect effect, occurring as a result of the Th2-type inflammation and eosinophilic infiltration affecting many tissues (Dent et al., 1997; Fukuda et al., 1997; Ye et al., 1997, see below) , recent electron microscopy studies show that cardiac myocytes exhibit several defects prior to the eosinophilic infiltration. Moreover, chimeric animals, in which all organs including the heart are BCL6+/+ while the lymphocytes are BCL6À/À (these animals were obtained by transferring bone marrow from BCL6À/À mice into sublethally irradiated BCL6+/+/RAG1À/À ones), show no myocarditis, although a massive eosinophilic infiltration is still observed in other tissues. Finally, in wild-type mice, BCL6 expression is induced 2 weeks after birth in heart myocytes. Altogether, these data suggest that heart myocytes lack an intrinsic prosurvival activity in BCL6À/À mice, with the myocarditis being therefore merely the consequence of this primary defect (Yoshida et al., 1999b) . However, these results do not completely rule out the possibility that myocarditis could be indirectly mediated by nonlymphoid BCL6À/À haematopoietic cells, especially macrophages. The latter indeed overproduce various chemokines when BCL6 is disrupted and thus are likely to contribute to the Th2-type inflammation in BCL6À/À mice (Toney et al., 2000) .
More recently, a screen in mouse embryo fibroblasts (MEF) carrying a thermosensitive version of SV40 T antigen has established that the retrovirus-driven expression of BCL6 efficiently abrogates a p19ARF/ p53-mediated senescence pathway and cooperates with activated ras (which alone induces premature MEF senescence) to fully transform these cells. Enforced BCL6 expression does not appear to affect the expression level of p19ARF nor its ability to activate p53. Rather, enforced BCL6 expression upregulates (presumably indirectly) the expression of the cyclin D1 gene, which is a critical target, since cyclin D1 knockout MEF are resistant to BCL6-induced immortalization (Shvarts et al., 2002) . This prosurvival effect of BCL6 is also demonstrated in primary human tonsillar B cells whose replicative life span in vitro is dramatically extended upon infection with a BCL6-encoding retroviral vector (Shvarts et al., 2002) . According to this study, BCL6 is a bonafide immortalizing oncogene. Together with the possible role of BCL6 as an antiapoptotic factor, these results are consistent with other studies reporting that expression of a dominant negative form of BCL6 in Bcell lines promotes cell death and cell cycle arrest at the G1 phase (Shaffer et al., 2000; Baron et al., 2002) . These data also suggest that in certain BNHL, BCL6 persistent expression improves the survival of the GC B cells, thereby making them more prone to 'successfully' undergo other oncogenic genetic changes (Figure 3 ).
BCL6 as a death-inducing gene
Not too surprisingly, the above conclusions are not valid in all cellular systems, suggesting a possible ambivalent role of BCL6 in transformation. Indeed, several studies have reported that enforced BCL6 expression triggers apoptosis. This has been shown in various cell lines, such as U2OS osteosarcoma cells using a tetracycline-regulated system (Albagli et al., 1999) , CV1 and HeLa cells using an adenoviral vector (Yamochi et al., 1999) , NIH 3T3 cells upon transient transfection (Zhang et al., 2001 ) and was also reported in a pro-B cell line (DIF9) as well as in mouse L cells (Zhang et al., 2001) . In CV1 cells, the induction of apoptosis by BCL6 is preceded by the downregulation of the genes encoding the apoptosis repressors BCLX(L) and BCL2. Altogether, these data have led some authors to suggest that high BCL6 expression may kill all the cells in which it is naturally not (or barely) expressed . Moreover, enforced BCL6 expression has also been shown to impair cell cycle progression, although in a different manner depending on the cell line. Indeed, U2OS cells induced to express BCL6 hardly progress throughout the S phase, while enforced BCL6 expression leads CV1 cells to accumulate in the G2/M phase (Albagli et al., 1999; Yamochi et al., 1999) . The existence of a link between the cell cycle alterations and the induction of apoptosis by BCL6 is uncertain, since it has been reported that BCL6-mediated apoptosis of CV1 cells does not require cell cycle arrest at the G2/M phase (Yamochi et al., 1999) . Obviously, the physiological relevance of such studies based on dramatically enforced BCL6 expression in established cell lines is questionable. However, a similar enforced expression of truncated BCL6 derivatives showing a reduced ability to repress transcription (Figure 1) does not lead to apoptosis (Albagli et al., 1999; Yamochi et al., 1999; Zhang et al., 2001 ) and has little effect on the cell cycle (Albagli et al., 1999) . Moreover, endogenous BCL6 may be an important mediator of the apoptosis triggered in HeLa cells by an activated version of the transcription factor AFX (AFX*). Indeed, AFX* upregulates the expression of endogenous BCL6, which in turn might directly repress BCLX(L) expression in these cells (Tang et al., 2002) . However, it has not been demonstrated that the upregulation of the endogenous BCL6 expression following AFX* expression is sufficient to trigger apoptosis (Tang et al., 2002) . Other pathways independent of BCLX(L) repression seem to exist, since overexpressed BCLX(L) does not counteract BCL6-induced apoptosis in NIH3T3 cells (Zhang et al., 2001) and overexpressed BCL6 does not affect BCLX(L) transcription in C2C12 myocytes (Kumagai et al., 1999) . However, and most importantly, it has been shown that primary macrophages derived from mice lacking BCL6 show enhanced survival in vitro compared to their wild-type counterparts (Tang et al., 2002) . Thus, the endogenous expression of BCL6 impairs cell survival in some nonestablished cells grown in vitro, suggesting that it could also sometimes have a negative influence on the cell survival in vivo. Hence, its 'accidental' downregulation could contribute to some BNHL cases, possibly at a late step (Ueda et al., 2002b) .
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BCL6 and cell differentiation
Role of BCL6 in GC B cells
The first indication of a role for BCL6 in normal B cells came from studies showing that BCL6 expression is tightly regulated during their differentiation. Indeed, immunohistochemical studies of normal lymphoid tissues show that BCL6 is selectively abundant in GC B cells (Cattoretti et al., 1995; Onizuka et al., 1995; Allman et al., 1996) , possibly, in part, as a consequence of a (post)-translational regulation (Allman et al., 1996) . Accordingly, BCL6 is generally expressed at both mRNA and protein levels in the transformed counterparts of GC B cells, hence in many BNHL, but not in B cell lines exhibiting a less (pre B) or more (plasma cells) differentiated phenotype (Cattoretti et al., 1995; Onizuka et al., 1995; Allman et al., 1996) . More directly, BCL6À/À mice show a normal lymphoid organ development and B lymphogenesis as well as T-cell-independent B-cell responses, but lack GC and consequently exhibit impaired T-cell-dependent antibody responses. Chimeric mice demonstrated that this defect is intrinsic to B cells, indicating that BCL6 selectively plays an essential role in GC B cells (Dent et al., 1997; Fukuda et al., 1997; Ye et al., 1997; Toney et al., 2000) . The in vivo tracking of splenic B cells expressing an inactive but detectable BCL6 truncated version produced by one type of 'BCL6À/À' mice suggests that BCL6 is essential for follicular B cells to differentiate into GC B cells and to proliferate (Ye et al., 1997) . However, BCL6 is strongly expressed in most, if not all, GC B cells, in both centroblasts and centrocytes that are, respectively, actively proliferating and resting cells (Cattoretti et al., 1995; Ye et al., 1997) . Accordingly, a search for BCL6 target genes in B cell lines reported that it represses genes encoding presumed cell cycle promoters (cyclin D2 and cyclin A2) as well as inhibitor (p27kip1) (Shaffer et al., 2000; Hosokawa et al., 2001) . In fact, although it has been proposed that BCL6 controls affinity maturation and apoptosis of GC B cells, possibly in part by regulating BCL2 and PCDC2 expression (Cattoretti et al., 1995; Yamochi et al., 1999; Baron et al., 2002; Tang et al., 2002) , no clear correlation has been observed in vivo between BCL6 expression and any particular fate of GC B cells (Fukuda et al., 1997; Ye et al., 1997) . This leads again to the idea that high BCL6 expression might buffer some general stresses -which remain to be defined -experienced by GC B cells (Fukuda et al., 1997) and/or is required for them to acquire and maintain their phenotype (Figure 3) .
In vitro studies provide further evidences for a 'maintenance' role of the GC phenotype by BCL6. Retrovirus-driven BCL6 expression inhibits the terminal differentiation of the BCL1 B cells as well as that of primary B cells (Reljic et al., 2000; Shaffer et al., 2000) . It does so, in part, by antagonizing the activity of the STAT3 transcription factor -a mediator of IL2 signalling that shares DNA-binding specificity with BCL6 -and hence by repressing the transcription of the gene encoding Blimp, a zinc finger transcription factor that plays a prominent role in promoting B-cell terminal differentiation (Reljic et al., 2000) . Accordingly, the expression of a dominant negative version of BCL6 in Raji B cells downregulates several genes that are characteristically expressed in GC cells, while it induces some, but not all, markers of terminal plasmacytic differentiation (Shaffer et al., 2000) . It is therefore likely that BCL6 also prevents premature terminal differentiation of GC B cells in vivo, thereby allowing affinity maturation of the immune response to occur, until it is shut off as the cells exit from GC (Reljic et al., 2000) . Therefore, alterations in BNHL that abrogate BCL6 downregulation would stabilize the GC phenotype by delaying or preventing terminal differentiation, thereby contributing to lymphomagenesis.
Role of BCL6 in memory T cells
BCL6 expression has been observed early in T cells (Fukuda et al., 1995) . Moreover, BCL6À/À mice overproduce Th2 cytokines and suffer Th2-type inflammations in multiple organs (Dent et al., 1997; Fukuda et al., 1997; Ye et al., 1997) . Whether BCL6 plays an intrinsic role in T cells yet remains unclear, as the disruption of BCL6 only in lymphoid cells (in either T, B, or both lineages) was shown to be insufficient to trigger the full-scale Th2-type inflammatory disease (Toney et al., 2000) . However, it has recently been reported that BCL6 negatively regulates IL5 transcription in Th2 cells, which may explain, in part, the overexpression of this cytokine in BCL6À/À mice (Dent et al., 1997; Arima et al., 2002) . It has also been very recently reported that mice lacking BCL6 have a reduced number of CD8 + (and CD4 + ) T-cells with a memory phenotype (CD44 + , Ly6C + ) and that this defect could be rescued upon expression of a BCL6 transgene under the control of a T cell-specific promoter . The expression of BCL6 has not yet been examined throughout the differentiation of memory CD8 + T-cells, but transfer experiments of purified precursor 'naı¨ve' BCL6À/À CD8 + T-cells into normal mice strongly suggest that this defect is cell-autonomous . Note however that indirect effects involving other types of T cells cannot be completely ruled out. Indeed, BCL6 plays a potent role in regulating the differentiation of CD4 + Th2 cells, which themselves strongly affect CD8 + T-cell differentiation (A Dent, personal communication), so that an even small fraction of contaminating BCL6À/À CD4 + Th2 cells might alter the fate of the injected CD8 + precursors. The too low number of memory T cells arising from the injected 'naı¨ve' BCL6À/À CD8 + T cells is not due to an increased apoptosis or (for a small part) to a reduced proliferation of these precursors . Rather, it appears that BCL6 is important for CD8 + memory T cells to maintain their characteristic phenotype. Indeed, upon deletion of BCL6, this phenotype appears abnormally transient -being rapidly 'crossed' and replaced by the CD44 À , Ly6C
+ onewhereas, conversely, it is too stable in BCL6-overexpressing cells. Interestingly, the stabilization of this .
Is BCL6 involved in permanent exit from the cell cycle of other cell types?
In contrast with what occurs in GC B cells, the expression of BCL6 does not drop but rather continuously rises upon terminal differentiation of numerous cell types. This has been shown in keratinocytes, skeletal myocytes, male germ cells and myeloid/monocytic cells upon monocytoid differentiation. In at least some of these cases, the increase in BCL6 protein level parallels the observed upregulation of the mRNA (Yoshida et al., 1996; Yamochi et al., 1997; AlbagliCuriel et al., 1998; Kumagai et al., 1999) (Figure 3) . Reciprocally, early observations also suggested that outside GC, BCL6 may contribute to stabilize lymphoid cells in the G0/G1 phase of the cell cycle. Indeed, the BCL6 mRNA level is high in both B and T resting lymphocytes from mouse spleen and human blood, but strongly drops upon their mitogenic activation in vitro and becomes stably minimal a few hours before their entry into the S phase (Allman et al., 1996) . Moreover, at least in skeletal myocytes and keratinocytes, the upregulation of BCL6 expression is not the consequence of a reversible growth arrest, but rather is linked with the definitive exit from the cell cycle accompanying terminal differentiation (Yoshida et al., 1996; AlbagliCuriel et al., 1998; Kumagai et al., 1999) . This suggests that a 'high' BCL6 expression contributes to induce and/ or maintain a terminally differentiated state in various cell types. Accordingly, the fact that BCL6-depleted myocytes undergo apoptosis does not reveal a protective role of BCL6 against apoptosis induced by serum starvation. It might rather reflect a more fundamental impairment of the ability of these cells to coordinate cessation of their growth and terminal differentiation, and/or to exit irreversibly from the cell cycle once they have started to differentiate (Albagli-Curiel et al., 1998) . Indeed, BCL6-depleted skeletal myocytes exhibit a phenotype similar to those lacking RB, which is required for differentiating myocytes to irreversibly lock their postmitotic state (Wang et al., 1997) . These data, together with the proapoptotic activity shown by BCL6 under some circumstances, further suggest how BCL6, like at least three other related proteins, could act as an 'antioncoprotein' whose insufficiency would also cause cancer. In some DLCL cases, BCL6 insufficiency may cause hyperactivation of IRF4, a transcription factor normally bound and repressed by BCL6 (Figure 1 ), thereby inducing unchecked proliferation (Alizadeh et al., 2000; Gupta et al., 2001) .
Conclusion and perspectives
Several ideas can be generated from this overview. The first one is that BCL6 exerts ambivalent effects on cell survival. This could help to understand its role in transformation, especially if both BCL6 'overexpression' (i.e. abnormally persistent expression through B-cell differentiation) and BCL6 'underexpression' turn out to be indeed oncogenic. However, our 'historical' propensity to consider all the reported cellular functions of BCL6 in the light of its proposed role in BNHL, a tendency certainly enhanced by the lack of definitive proof causally linking BCL6 alterations to BNHL, is probably not entirely legitimate, given the diversity of the model systems. In fact, as emphasized above, by several aspects, GC B cells appear somewhat atypical with respect to BCL6 regulation. Presumably, the accelerated molecular evolution specifically undergone by human BCL6 regulatory regions in these cells through somatic hypermutations generates a particular plasticity to their fate, including towards neoplasia. The recent suggestion that BCL6 is expressed in certain solid tumours (Shvarts et al., 2002) may offer other frameworks to consider the available data about its cellular functions.
Another possible link between some data is that BCL6 stabilizes particular states of differentiation. This is demonstrated in memory T cells whose phenotypic stability depends to some degree on BCL6 . It is probably even clearer in B cells, in which BCL6 might well be absolutely required for these cells to stay at the GC stage, despite extensive proliferation. This might also explain the frequent increase of BCL6 expression upon permanent exit of the cell cycle and also partially account for the protective effect of endogenous BCL6 expression in some cells in vivo as well as in some primary and established cells in vitro. Interestingly, this aspect of BCL6 cellular function resembles what has been shown for various POK proteins in vertebrates and Drosophila. Indeed, PLZF appears to be crucial to maintain the quiescent, undifferentiated state of haematopoietic progenitors (Shaknovich et al., 1998) . Similarly, in Drosophila, TTK, whose degradation upon MAPK kinase activation strikingly parallels that undergone by BCL6, is required to maintain glial differentiation Dickson, 1998; Niu et al., 1998; Badenhorst, 2001) . Moreover, the Drosophila GAGA factor as a component of some Polycomb complexes is also involved in the stabilization of transcriptional regulations and differentiation patterns (Shaknovich et al., 1998; Horard et al., 2000; Busturia et al., 2001) .
In addition, as often proposed, BCL6 may play a more direct protective role against some 'stresses' encountered by cells in vivo as well as in vitro. As pointed out by the high expression and essential function of BCL6 in GC B cells, including when these cells are very actively proliferating and undergo hypermutations, such stresses could be related to DNA damages. Reinforcing this notion, somatic hypermutations are associated with DNA double-strand breaks (Pasqualucci et al., 2001) , which interestingly also occur upon meiotic crossing over in spermatocytes I precisely when BCL6 appears to also have a vital function (Kojima et al., 2001) . Moreover, cellular senescence, which is counteracted by BCL6 in an in vitro model, has been proposed to result, at least partly, from the progressive accumulation of genetic damage (Sherr and DePinho, 2000; Rubin, 2002) . Finally, both BCL6 and another POK protein FAZF (TZFP) have been shown to associate with BrdU-containing DNA, and the interaction between FAZF and FANCC, encoded by a gene linked to the Fanconi Anemia, further suggests its involvement in DNA repair Dai et al., 2002) . Another, nonmutually exclusive hypothesis is that BCL6 would be connected to redox pathways and would protect the cells against metabolically induced oxidative injuries. In this regard, it is noteworthy that class I HDACs, which are partners of BCL6, form complexes containing a protein homologous to FADdependent oxidoreductases (Humphrey et al., 2001 ). This hypothesis is consistent with the particular sensitivity of cardiac -but not of skeletal -myocytes to BCL6 deletion in vivo. Indeed, the heart requires strong antioxidant defences and is more severely damaged when manganese superoxide dismutase, an intramitochondrial free radical scavenging protein maintaining the integrity of mitochondrial enzymes, is lacking (Li et al., 1995; Yoshida et al., 1999b) . Interestingly, mitochondria, which generate the majority of oxygen radicals and play crucial functions in apoptosis and senescence, are altered in both damaged cardiac myocytes and sperm cells lacking BCL6 (Yoshida et al., 1999b; Kojima et al., 2001 ). However, it should be recalled that not all the current data support a protective role of BCL6, as for instance its deletion does not affect the survival of CD8 + T cells, and even increases that of primary macrophages in vitro. In fact, it is increasingly clear that any protein, rather than having 'intrinsic', stable, activities, acts according to what chance and intracellular context make it 'meets' (McKnight, 2001) . It is thus likely that the diverse activities of BCL6 on cell survival and transformation may reflect different interactions at least with proteins and DNA, as it has been exemplified for GAGA to explain its involvement in numerous aspects of DNA metabolism and transcriptional regulations (Tsukiyama and Wu, 1995; Strutt et al., 1997; Espinas et al., 2000; Horard et al., 2000; Xiao et al., 2001) . The links between the activities of BCL6 and its interactions, including those presumed to mediate transcriptional repression, are still largely unknown and deserve further work in the future.
